Kura Oncology’s encouraging cancer drug data could unlock multi‑billion‑dollar market opportunity

Kura Oncology’s encouraging clinical data for its cancer drug programs, particularly the AML inhibitor ziftomenib and its FTI darlifarnib, have highlighted a potential multi‑billion‑dollar market opportunity in leukemia and solid tumors.

Kura Oncology and partner Kyowa Kirin estimate the U.S. market for frontline ziftomenib in acute myeloid leukemia could reach up to $3 billion annually, significantly exceeding the $2 billion reference in your query.

Updated frontline ziftomenib + 7+3 combination data presented in 2026 show 90–96% complete remission rates and deep MRD negativity in NPM1‑mutant and KMT2A‑rearranged AML, reinforcing the drug’s potential as a new standard‑of‑care regimen.

Darlifarnib‑based combination data in renal cell carcinoma and other solid tumors show 33–50% objective response rates in heavily pretreated patients, suggesting a broad opportunity to overcome resistance to existing kinase inhibitors and expand the addressable market.